PURPOSE We wanted to determine the association between consumption of barley and changes in plasma lipids in healthy and hypercholesterolemic men and women.
INTRODUCTION
A ccording to the guidelines of the National Cholesterol Education Program (NCEP), approximately 30% of Americans have undesirably high serum cholesterol concentrations. 1 High serum lipid levels, including total cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides, are a major cause of coronary atherosclerosis. 1 Any LDL cholesterol concentration above 100 mg/dL appears to be atherogenic and the higher the level, the greater the risk. 1 Although elevated LDL cholesterol plays a role in the development of the coronary plaque instability, lowering LDL cholesterol stabilizes plaques and reduces the likelihood of acute coronary syndromes. 1 Lowering serum cholesterol reduces the risk of coronary heart disease.
The effect of dietary fi ber on cholesterol metabolism has been studied extensively. 2, 3 Barley and oats have a similar concentration of soluble fi bers called β-glucan (3.5%-5.9% of the dry matter), whereas wheat and rice do not posses this constituent type of fi ber. 4 Unlike wheat and rice, 5-10 a diet high in β-glucan has been shown to slow gastric emptying, digestion, and absorption. 11 These effects are associated with increased excretion of bile acids and neutral sterols, increased catabolism of cholesterol, and reduced absorption of cholesterol and fat. 12, 13 Although the antihyperlipidemic effects of oats have been extensively studied, there are fewer barley studies, and fi ndings have shown more Ripple Talati, PharmD 1, 2 William L. Baker, PharmD 14,15 Some reasons for inconsistencies in the barley studies may be explained by differences in the β-glucan dose, the molecular size of β-glucan, the composition of dietary food, the process of food preparation, and the initial variation in cholesterol level. Even though several clinical trials 10, [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] have investigated the impact of barley β-glucan on total cholesterol, LDL cholesterol, highdensity lipoprotein (HDL) cholesterol, and triglycerides, a meta-analysis assessing these effects has not been published. We therefore sought to perform a meta-analysis of randomized controlled trials of barley to better characterize its effect on various lipid parameters.
METHODS
Was conducted a systematic literature search of MED-LINE, EMBASE, CINAHL, Web of Science, the Cochrane Library, and the Natural Medicines Comprehensive Database from the earliest possible date through January 2008. Our search strategy used the Medical Subject Headings (MeSH) and text key words: "β-glucan," "barley" and "lipids," "serum cholesterol," "total cholesterol," "low-density lipoproteins," "high-density lipoproteins," "LDL," "HDL," "triglycerides," or "hypercholesterolemia." This search was then limited to clinical trials in humans. We also performed a manual search of references from retrieved articles. When applicable, we made an effort to contact investigators for clarifi cation or additional data (although no additional data were acquired).
To be included in this meta-analysis, studies had to be randomized controlled trials of barley and report data on at least 1 of the following lipid parameters: total cholesterol, LDL cholesterol, HDL cholesterol, or triglycerides. Both parallel and crossover trials were eligible for inclusion; however, crossover trials had to have at least a 4-week washout period. If this criterion was not met, when possible, we included only the fi rst phase of each crossover trial.
A more detailed description of the methods can be found in the Supplemental Appendix, available online at http://www.
annfammed.org/cgi/content/full/ 7/2/157/DC1.
We treated the mean change in lipid parameters from baseline as a continuous variable, and the weighted mean difference (WMD) and its 95% confi dence interval (CI) were calculated as the difference between the mean in the β-glucan and control groups using a DerSimonian and Laird random-effects model. 30 For parallel trials, we calculated net changes in each of these study parameters as the difference (β-glucan minus control) of the changes (baseline minus follow-up) in the mean values (also referred to as the change score). For crossover trials, we calculated net changes as the mean difference in values at the end of the β-glucan and control periods. Standard statistical methods were used to impute change scores, as suggested by Follman and colleagues. 31 Statistical heterogeneity was addressed using the I 2 statistic. Visual inspection of funnel plots, Egger's weighted regression statistics, and the trim and fi ll method was used to assess for the presence of publication bias. 32 Sensitivity analysis was conducted to assess the impact of double-blinding, the use of crossover methodology ,and the use of a fi xed-effects model (Mantel-Haenszel methodology). 33 Additionally, subgroup analyses were conducted to assess the effect of using or not using concurrent dietary modifi cations and to asses the effect on only hypercholesterolemic patients. Statistics were performed using StatsDirect statistical software, version 2.4.6 (StatsDirect Ltd, Cheshire, England). A P value of <.05 was considered statistically signifi cant for all analyses.
RESULTS
The initial search yielded a total of 22 studies for fulltext review. For reasons depicted in Figure 1 , 14 of 6 Reported HDL data the 22 studies were excluded; therefore, a total of 8 randomized controlled trials 10, [16] [17] [18] [19] [20] [21] [22] (evaluating 391 participants) were included in this meta-analysis (Table  1) . Five of the studies 10, [16] [17] [18] 20 were conducted using a parallel study design, whereas 2 studies 19,22 used a crossover design with a 4-week washout period, and 1 study 21 used a crossover design with no washout period and was treated as a parallel trial by taking into account only the fi rst phase of the study data.
Each study enrolled relatively few participants (median sample size, 30 participants; range, 10-155 participants) and had a short duration of treatment (median duration, 4 weeks; range, 4-12 weeks). The dosage of β-glucan reported in included studies ranged from 3 to 10 g/d (median dose, 7 g/d) and was administered in various forms, including pearled barley, barley bran fl our, oil extracts in capsules, barley concentrates, barley-containing beverages, and gelling agents. Only 2 studies 17, 20 administered barley along with some type of dietary modifi cation. Of the 8 studies, 6 were not double-blind. 10, [18] [19] [20] [21] [22] Three of the 8 studies were industry funded. 16, 17, 22 Upon meta-analysis, participants consuming barley had signifi cantly greater reductions in total cholesterol, LDL cholesterol, and triglycerides, but not HDL cholesterol compared with control participants (Table 2, Figure 2 ). No statistical heterogeneity was observed in any of these analyses (I 2 = 0% for all). Visual inspection of funnel plots (not shown) suggested a low likelihood of publication bias. This fi nding was further supported by Egger's weighted regression statistic P values, which also suggested that publication bias was unlikely for all analyses except total cholesterol (P = .02). After recalculating effect size estimates using trim and fi ll methods, barley's effect was not significantly altered for triglycerides. For total cholesterol, LDL cholesterol, and HDL cholesterol, the trim and fi ll analysis suggests that as many as 4 studies for total cholesterol and 3 studies for LDL cholesterol and HDL cholesterol could potentially exist for each endpoint; however, barley still had a signifi cant, although reduced, effect when these theoretically "missing" studies were imputed for total cholesterol and LDL cholesterol. For HDL cholesterol, the original analysis did not show signifi cance, but after imputing the 3 "missing" studies from the trim and fi ll, it was statistically signifi cant for this endpoint.
Upon subgroup and sensitivity analysis, similar results were seen for all of the study endpoints when crossover or non-double-blinded studies were excluded, except the effect of barley on triglycerides lost statistical signifi cance (Table 2) . When a fi xedeffects model was used, the results did not change. When studies evaluating barley in only hypercholesterolemic patients were analyzed, the effect of barley on triglycerides lost statistical signifi cance but still HMW or LMW = high or low molecular weight β-glucan; NR = not reported; step I diet = diet consisting total fat to ≤30% of total calories, saturated fat to ≤10% of total calories, and cholesterol to 300 mg/d.
a Number of patients evaluated.
b Crossover trial treated as parallel trial with only the fi rst phase of the study data taken into account.
trended toward a reduction. When studies using and not using dietary modifi cation were assessed separately, the effect of barley on serum lipids qualitatively appeared more robust when combined with dietary modifi cations.
DISCUSSION
In our meta-analysis of 8 randomized controlled trials, participants receiving barley had statistically significant reductions in total cholesterol (-13 mg/dL), LDL cholesterol (-10 mg/dL), and triglycerides (-12 mg/dL) compared with control group participants. Because studies have shown that for each milligram per deciliter reduction in a patient's LDL cholesterol level, their relative risk of having a coronary heart disease event is decreased by 1%, this modest reduction in LDL cholesterol observed with barley is likely clinically significant as well. 34 This reduction in total cholesterol and LDL cholesterol is in line with that found for oat-derived β-glucan. In a meta-analysis of oats containing 2 to 10 g/d of β-glucan, there was a net change resulting from soluble fi ber ingested of -3.1 mg/dL to -15.5 mg/dL for total cholesterol, and -2.9 mg/dL to -14.3 mg/dL for LDL cholesterol. 35 Barley and oats have similar concentrations of β-glucans (3.5%-5.9% of the dry matter), the proposed active ingredient in both soluble fi bers, so a similar magnitude of total cholesterol or LDL cholesterol reductions is plausible. 4 In the meta-analysis of oats by Brown and colleagues, however, changes of -0.08 to -0.4 mg/dL were noted for HDL cholesterol, and changes of 1.06 to 5.3 mg/dL were noted for triglycerides, which is in contrast to our meta-analysis, in which with barleyderived β-glucan we saw a nonsignifi cant increase of 1 mg/dL for HDL cholesterol and a signifi cant reduction of 12 mg/dL in triglycerides compared with a control group. 35 In addition, Brown and colleagues found a dose-response relationship when evaluating studies of soluble fi bers in the practical dose range (<10 g/d). 35 That review, however, included 67 clinical trials evaluating a variety of soluble fi bers (not including barley). Thus, their analysis was appropriately powered to evaluate dose response. In comparison, our meta-analysis included 8 studies, only 6 of which reported a β-glucan dose (75% of total patient population), making it diffi cult to conduct a dose-response analysis. At least 10 studies are recommended to provide adequate power. 36 The Food and Drug Administration (FDA) has stated that daily intakes of 3 g or more of soluble fi ber CI = confi dence interval; LDL = low-density lipoprotein; HDL = high-density lipoprotein; + = analysis-imputed missing studies.
Note: All results reported as weighted mean differences.
(β-glucan) in whole oats or barley may reduce the risk of heart disease by its ability to lower total cholesterol and LDL cholesterol. 37, 38 Our meta-analysis results support this FDA decision, because 3 to 10 g of β-glucan from various forms of barley lowered total cholesterol, LDL cholesterol, and triglycerides in the study participants. Furthermore, a signifi cant reduction in total cholesterol and LDL cholesterol was found regardless of whether a low-fat or step I diet was mandated equally in both arms of the studies. This fi nding is important because of the potential for a dietary substitution effect. If study participants are replacing their normal foods (eg, eggs, bacon, sausage) with barley, it may be diffi cult to discern whether the improvements in cholesterol resulted from the healthier diet or from barley.
That signifi cant reductions in total cholesterol and LDL cholesterol were seen regardless of whether diet modifi cations were mandated equally in both study groups helps guard against the issue of dietary substitution and strengthens the benefi cial effects of barley use.
There are some limitations to this meta-analysis that should be noted. First, we included crossover and parallel studies. Crossover studies have methodological advantages compared with parallel studies, because patients act as their own controls; however, an adequate washout period is necessary. As such, we did not include trials that did not explicitly state the presence and duration of the washout period or trials that had a washout period of fewer than 4 weeks, in which case, we only included the fi rst phase of the study when possible. The only noteworthy change seen upon conducting a sensitivity analysis excluding crossover studies was loss of statistical signifi cance in the triglycerides endpoint. Second, as with any meta-analysis, the potential for publication bias is a concern. Although visual inspection of our meta-analysis' funnel plot could not rule out the possibility of publication bias, review of Egger's weighted regression statistics and trim and fi ll analyses showed that it was unlikely that publication bias signifi cantly affected our study results. Finally, we did not evaluate the potential for harms with barley. Based upon available data, barley appears to be well tolerated, with fl atulence and abdominal discomfort being reported as the most common adverse effects, but there is not adequate power to look for other less common adverse effects. 17 The results of our study support the routine use of soluble fi bers in the diets of adult patients with and without hypercholesterolemia. Barley adds another source of soluble fi bers, in addition to oats, psyllium, pectin, and guar gum that patients can consume as part of a healthy diet. 35 Larger randomized clinical trials are warranted to better characterize the potential for a dose-response relationship with barley β-glucan. Health practitioners should feel comfortable recommending barley β-glucan to their patients to help reduce total cholesterol and LDL cholesterol concentrations as recommended by the NCEP guidelines. 
